CSE: TELI

Investors

CSE: TELI

OTCQB: TELI

DOWNLOAD THE INVESTOR DECK

Our Track Record

The value of our technology innovation is backed by our financial performance:

  • Positive revenue in our first full fiscal year (FY22)
  • 375% growth in revenue from FY 2022 to FY 2023

We have also succeeded in commercializing our first product. Within a year of launch, our DirectInject-LC™ technology was deployed by 13 of the top 20 pharma companies in the world. This product is now globally globally distributed by METTLER TOLEDO, a market leader in scientific instrumentation. View the Press Release here

Our Leadership & Expertise

Scientific leadership includes:

  • 2-time Nobel Prize Winner in Chemistry: Dr. Barry Sharpless (Advisor)
  • Globally-recognized expert in process chemistry, automation, and self-driving labs: Dr. Jason Hein (CTO, Director)
  • An R&D team that has collectively authored over 450 peer-reviewed publications and 34 patents

 

Highlights from our management team:

  • Ex-president of METTLER TOLEDO AutoChem, the market leader in lab and automation tools for biopharmaceutical and chemical development, Henry Dubina (CEO, Chairman)

OUR PARTNERS & CLIENTS

Our clients include the biggest names in pharmaceutical development, along with key innovators in engineering and chemical manufacturing. We also collaborate closely to develop technology with instrumentation companies ( METTLER TOLEDO, Mott), government bodies (Natural Resources Canada, the Canadian Mining Innovation Commercialization Network: MICA), and academic institutions ( Scripps Research).

Our Intellectual Property

Our IP portfolio includes  discoveries in both pharmaceutical and fine chemical manufacturing.  We have patented scalable routes to indole-based therapeutics, and are pursuing two patents related to the supply of battery materials: one low-temperature route to produce lithium sulfide, and one efficient purification process for battery-quality lithium carbonate.

Our patenting activities place us among the 2% of Canadian SMEs to hold patents.

Corporate Governance

COMPANY POLICIES

2024 AGM DOCUMENTATION

2023 AGM DOCUMENTATION

Financial Statements and MD&A

KEEP UP-TO-DATE: SUBSCRIBE TO OUR NEWSLETTER